ANI Pharmaceuticals Inc (ANIP)
64.90
+1.44
(+2.27%)
USD |
NASDAQ |
May 31, 16:00
64.95
+0.05
(+0.08%)
After-Hours: 20:00
ANI Pharmaceuticals Price to Book Value: 3.01 for May 31, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 3.01 |
| May 30, 2024 | 2.943 |
| May 29, 2024 | 2.926 |
| May 28, 2024 | 2.932 |
| May 24, 2024 | 2.844 |
| May 23, 2024 | 2.799 |
| May 22, 2024 | 2.860 |
| May 21, 2024 | 2.862 |
| May 20, 2024 | 2.863 |
| May 17, 2024 | 2.849 |
| May 16, 2024 | 2.958 |
| May 15, 2024 | 3.006 |
| May 14, 2024 | 3.062 |
| May 13, 2024 | 3.123 |
| May 10, 2024 | 3.156 |
| May 09, 2024 | 3.056 |
| May 08, 2024 | 3.043 |
| May 07, 2024 | 3.094 |
| May 06, 2024 | 3.124 |
| May 03, 2024 | 3.119 |
| May 02, 2024 | 3.115 |
| May 01, 2024 | 3.088 |
| April 30, 2024 | 3.064 |
| April 29, 2024 | 3.040 |
| April 26, 2024 | 3.034 |
| Date | Value |
|---|---|
| April 25, 2024 | 3.015 |
| April 24, 2024 | 3.037 |
| April 23, 2024 | 3.070 |
| April 22, 2024 | 3.046 |
| April 19, 2024 | 3.040 |
| April 18, 2024 | 2.998 |
| April 17, 2024 | 3.040 |
| April 16, 2024 | 3.043 |
| April 15, 2024 | 3.078 |
| April 12, 2024 | 3.105 |
| April 11, 2024 | 3.162 |
| April 10, 2024 | 3.108 |
| April 09, 2024 | 3.112 |
| April 08, 2024 | 3.138 |
| April 05, 2024 | 3.140 |
| April 04, 2024 | 3.154 |
| April 03, 2024 | 3.121 |
| April 02, 2024 | 3.097 |
| April 01, 2024 | 3.151 |
| March 31, 2024 | |
| March 28, 2024 | 3.352 |
| March 27, 2024 | 3.379 |
| March 26, 2024 | 3.375 |
| March 25, 2024 | 3.377 |
| March 22, 2024 | 3.376 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.239
Minimum
Jun 16 2022
4.965
Maximum
Jul 30 2019
2.547
Average
2.254
Median
Jan 06 2022
Price to Book Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.897 |
| ADMA Biologics Inc | 14.40 |
| Annovis Bio Inc | -- |
| United Therapeutics Corp | 2.289 |
| Moderna Inc | 4.262 |
Price to Book Value Related Metrics
| PE Ratio | 41.08 |
| PS Ratio | 2.374 |
| Price to Free Cash Flow | 12.92 |
| Price | 64.90 |
| Earnings Yield | 2.43% |
| Market Cap | 1.360B |
| Operating PE Ratio | 23.35 |
| Normalized PE Ratio | 62.42 |